Type: Public
On the web: http://www.watson.com
Employees: 6,030
Employee growth: 3.4%

Watson Pharmaceuticals tries to have the best of both worlds, with operations in both the generics market and the higher-profit-margin branded drug business. The company's broad generics portfolio of about 160 products includes treatments for hypertension and pain, as well as smoking cessation products, antidepressants, and oral contraceptives. Its line of some 30 branded drugs is focused on urology and nephrology and marketed to specialist physicians in the US. Additionally, Watson distributes its own and third-party products to independent pharmacies and health care providers in the US through its Anda and Valmed subsidiaries.

Key numbers for fiscal year ending December, 2010:
Sales: $3,566.9M
One year growth: 27.7%
Net income: $184.4M
Income growth: (16.9%)

Officers:
Chairman: Andrew L. Turner
President, CEO, and Director: Paul M. Bisaro
EVP and CFO: R. Todd Joyce

Competitors:
Mylan
Novartis
Teva

© 2012 Hoover's, Inc. All rights reserved.